Ticker: IMRX

Company Overview Immuneering Corporation (NASDAQ: IMRX) is a clinical-stage oncology company focused on developing therapies targeting RAS and RAF mutations through novel approaches in cancer treatment. Recent Developments - Launched a Phase 1/2a clinical trial for lead candidate IMM-1-104; inter...